Information Provided By:
Fly News Breaks for February 7, 2020
Feb 7, 2020 | 05:34 EDT
Piper Sandler analyst William Quirk lowered his price target for Myriad Genetics to $20 from $22 saying the company missed expectations for the sixth quarter in a row in Q2. He keeps a Neutral rating on the shares.
News For MYGN From the Last 2 Days
There are no results for your query MYGN